Total Payments
$207,867
2024 Payments
$7,001
Companies
10
Transactions
128
Payment Breakdown by Category
Consulting$182,482 (87.8%)
Other$13,000 (6.3%)
Travel$6,534 (3.1%)
Research$3,471 (1.7%)
Food & Beverage$2,380 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $182,482 | 66 | 87.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,000 | 4 | 6.3% |
| Travel and Lodging | $6,534 | 24 | 3.1% |
| Unspecified | $3,471 | 1 | 1.7% |
| Food and Beverage | $2,380 | 33 | 1.1% |
Payments by Type
General
$204,395
127 transactions
Research
$3,471
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ACADIA Pharmaceuticals Inc | $110,306 | 69 | $0 (2022) |
| Eisai Inc. | $47,460 | 27 | $0 (2024) |
| Genentech USA, Inc. | $19,455 | 13 | $0 (2022) |
| Corium, LLC | $8,490 | 4 | $0 (2022) |
| Biogen, Inc. | $6,943 | 2 | $0 (2021) |
| Avanir Pharmaceuticals, Inc. | $5,766 | 5 | $0 (2018) |
| Grifols Shared Services North America, Inc. | $4,285 | 4 | $0 (2019) |
| GlaxoSmithKline, LLC. | $3,000 | 1 | $0 (2024) |
| Novo Nordisk Inc | $2,040 | 2 | $0 (2021) |
| Merck Sharp & Dohme Corporation | $122.08 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,001 | 7 | Eisai Inc. ($4,001) |
| 2022 | $20,829 | 14 | ACADIA Pharmaceuticals Inc ($10,359) |
| 2021 | $23,243 | 11 | ACADIA Pharmaceuticals Inc ($8,500) |
| 2020 | $24,850 | 12 | ACADIA Pharmaceuticals Inc ($23,500) |
| 2019 | $61,756 | 44 | ACADIA Pharmaceuticals Inc ($34,955) |
| 2018 | $58,235 | 35 | ACADIA Pharmaceuticals Inc ($29,861) |
| 2017 | $11,953 | 5 | Eisai Inc. ($8,700) |
All Payment Transactions
128 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/30/2024 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $55.61 | General |
| 07/30/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $124.26 | General |
| Category: Neurology | ||||||
| 04/24/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 04/03/2024 | Eisai Inc. | Leqembi (Drug) | Consulting Fee | Cash or cash equivalent | $3,710.00 | General |
| Category: Neurology | ||||||
| 03/18/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $49.98 | General |
| Category: Neurology | ||||||
| 03/18/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $48.73 | General |
| Category: Neurology | ||||||
| 03/18/2024 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $12.24 | General |
| Category: Neurology | ||||||
| 12/07/2022 | Corium, LLC | Adlarity (Drug) | Consulting Fee | Cash or cash equivalent | $3,500.00 | General |
| Category: Treatment of dementia of the Alzheimers type | ||||||
| 10/19/2022 | Corium, LLC | ADLARITY (Drug) | Consulting Fee | Cash or cash equivalent | $2,240.00 | General |
| Category: Treatment of dementia of the Alzheimers type | ||||||
| 09/01/2022 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 06/09/2022 | Corium, LLC | Adlarity (Drug) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Treatment of dementia of the Alzheimers type | ||||||
| 05/18/2022 | Corium, LLC | Adlarity (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: Treatment of dementia of the Alzheimers type | ||||||
| 05/17/2022 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Consulting Fee | Cash or cash equivalent | $5,250.00 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 05/17/2022 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Consulting Fee | In-kind items and services | $223.52 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 05/17/2022 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Consulting Fee | In-kind items and services | $81.90 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 05/17/2022 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $27.46 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 05/17/2022 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Food and Beverage | In-kind items and services | $26.33 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 04/21/2022 | Genentech USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,440.00 | General |
| 04/20/2022 | EISAI INC. | Dayvigo (Drug) | Consulting Fee | Cash or cash equivalent | $540.00 | General |
| Category: Neurology | ||||||
| 03/14/2022 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 03/14/2022 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 11/16/2021 | Genentech USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,935.00 | General |
| 10/08/2021 | Eisai Inc. | Dayvigo (Drug) | Consulting Fee | Cash or cash equivalent | $1,620.00 | General |
| Category: Neurology | ||||||
| 08/06/2021 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Consulting Fee | Cash or cash equivalent | $2,000.00 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
| 07/23/2021 | ACADIA Pharmaceuticals Inc | NUPLAZID (Drug) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| Category: PARKINSONS DISEASE PSYCHOSIS | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Intuition: a Brain Health Study | Biogen, Inc. | $3,471 | 1 |
About Davangere Devanand
Davangere Devanand is a Geriatric Psychiatry healthcare provider based in Binghamton, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/20/2007. The National Provider Identifier (NPI) number assigned to this provider is 1972628881.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Davangere Devanand has received a total of $207,867 in payments from pharmaceutical and medical device companies, with $7,001 received in 2024. These payments were reported across 128 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($182,482).
Ad
Practice Information
- Specialty Geriatric Psychiatry
- Location Binghamton, NY
- Active Since 03/20/2007
- Last Updated 07/08/2007
- Taxonomy Code 2084P0805X
- Entity Type Individual
- NPI Number 1972628881
Products in Payments
- NUPLAZID (Drug) $100,306
- Adlarity (Drug) $6,250
- DISEASE EDUCATION (Drug) $6,000
- Leqembi (Drug) $3,945
- Albutein (Biological) $3,800
- ADUHELM (Biological) $3,471
- ADLARITY (Drug) $2,240
- Dayvigo (Drug) $2,160
- Flebogamma DIF (Biological) $485.09
- None (Drug) $124.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.